CH
NKGN

CVI Holdings’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

CVI Holdings’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-150,000
Closed -$1.52M – 311
2023
Q1 		$1.52M Buy
+150,000
New +$1.51M 0.57% 60
2022
Q4 		– Sell
-150,000
Closed -$1.46M – 663
2022
Q3 		$1.46M Hold
150,000
– – 0.11% 282
2022
Q2 		$1.46M Hold
150,000
– – 0.11% 306
2022
Q1 		$1.46M Hold
150,000
– – 0.1% 331
2021
Q4 		$1.45M Hold
150,000
– – 0.1% 319
2021
Q3 		$1.45M Buy
+150,000
New +$1.46M 0.09% 315

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

CVI Holdings's NKGN Position: Q2 2023 in Review

CVI Holdings sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 150,000 shares — an estimated $1.52M sold.

CVI Holdings first reported a position in NKGN in Q3 2021 and held it in 6 quarters. The position peaked at $1.52M in Q1 2023. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • CVI Holdings reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • CVI Holdings sold 150,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $1.52M.
  • CVI Holdings first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • CVI Holdings's NKGen Biotech, Inc. Common Stock position peaked at $1.52M in Q1 2023.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on CVI Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.